Antibody Drug Conjugates Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technology, Application, Target, Distribution Channel, and Geography

Description

List of Tables

The antibody drug conjugates market is expected to reach US$ 38.07 billion by 2031 from US$ 8.10 billion in 2023; the market is estimated to grow at a CAGR of 21.3% during 2023-2031. Major factors driving the market growth include strategic investments by key players and increase in availability of approved products. Further, expansion into new indications is likely to boost the market during the forecast period. However, manufacturing challenges are among the market deterrents.

Strategic investments such as mergers, acquisitions, partnerships, and collaborations among key players in the antibody-drug conjugates (antibody-drug conjugates) market significantly influence its growth and development. These strategies enable companies to pool resources, share expertise, and leverage complementary strengths to enhance their competitive edge in a rapidly evolving landscape. Amid the search for innovative cancer therapies, antibody-drug conjugates have gained attention for their ability to selectively target and destroy cancer cells while sparing healthy tissues, thereby minimizing side effects. Consequently, major pharmaceutical and biotechnology firms are increasingly engaging in strategic alliances to accelerate the development and commercialization of antibody-drug conjugates.

As the market becomes more competitive, companies seek to acquire or merge with other firms that have promising antibody-drug conjugate technologies or candidates in their pipelines. For instance, larger pharmaceutical companies acquire smaller biotech firms specializing in antibody-drug conjugate development to quickly incorporate advanced technologies into their existing product lines. Such acquisitions help the acquiring company enhance its portfolio and gain access to novel linker technologies, payloads, and targeting mechanisms that can improve the efficacy and safety profiles of its therapeutics. In October 2024, GlycoMimetics, Inc. entered into an acquisition agreement with Crescent Biopharma, Inc., a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Upon completion of the transaction, the company plans to operate under the name Crescent Biopharma, Inc. In March 2024, Johnson & Johnson acquired Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform, to design and develop next-generation antibody-drug conjugates. In September 2024, Araris Biotech AG, a Swiss oncology and biotechnology company involved in developing next-generation antibody-drug conjugates, announced making an agreement with Innate Pharma. Under the agreement, Innate would assign Araris a portfolio of patents related to its transglutaminase conjugation technology.

The competitive landscape in the antibody-drug conjugates market is characterized by a high level of activity from key players engaging in strategic investments. This dynamism encourages innovation and improvement as companies strive to differentiate their products and establish leadership in the market. The influx of capital investment into oncology attracts new entrants, leading to a more vibrant ecosystem encouraging innovative ideas. Strategic investments through mergers, acquisitions, partnerships, and collaborations play a pivotal role in driving the growth of the antibody-drug conjugates market. These investments create a synergistic environment by enhancing product portfolios, improving manufacturing processes, and fostering innovation to propel the development of effective and targeted cancer therapies.

The comparative company analysis evaluates and categorizes the antibody drug conjugates market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global Antibody Drug Conjugates Market. The key market players are ADC Therapeutics SA, Pfizer Inc, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Co Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, Takeda Pharmaceutical Co Ltd, Merck KGaA, Johnson & Johnson, Bristol-Myers Squibb Co, BioNTech SE, AbbVie Inc.

Based on technology, the antibody drug conjugates market is segmented into cleavable linker and non-cleavable linker. In 2023, the cleavable linker segment held the largest share of the market. Based on application, the antibody drug conjugates market is segmented into blood cancer, brain cancer, breast cancer, ovarian cancer, lung cancer and others. In 2023, the breast cancer segment held the largest share of the market.

Various organic and inorganic strategies are adopted by companies operating in the antibody drug conjugates market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the antibody drug conjugates market are listed below.

In November 2024, AstraZeneca constructed a US$ 1.5 billion manufacturing facility in Singapore dedicated to antibody drug conjugates (ADCs), which will improve the global supply of its ADC portfolio. ADCs are advanced treatments designed to deliver powerful cancer-fighting agents directly to cancer cells using targeted antibodies.

Product Code: TIPRE00003494

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Antibody Drug Conjugates Market Landscape

4.1 PEST Analysis
4.2 Ecosystem Analysis
- 4.2.1 List of Vendors in the Value Chain
- 4.2.2 List of Approved Products
- 4.2.3 Pipeline Analysis
- 4.2.4 Regulatory Guidelines

5. Antibody Drug Conjugates Market - Key Market Dynamics

5.1 Antibody Drug Conjugates Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Strategic Investments by Key Players
- 5.2.2 Increase in Availability of Approved Products
5.3 Market Restraints
- 5.3.1 Manufacturing Challenges
5.4 Market Opportunities
- 5.4.1 Expansion into New Indications
5.5 Future Trends
- 5.5.1 Expanding Clinical Trial Pipeline
5.6 Impact of Drivers and Restraints:

6. Antibody Drug Conjugates Market - Global Market Analysis

6.1 Antibody Drug Conjugates Market Revenue (US$ Million), 2021-2031
6.2 Overview
6.3 Antibody Drug Conjugates Market Forecast Analysis

7. Antibody Drug Conjugates Market Analysis - by Technology

7.1 Cleavable Linker
- 7.1.1 Overview
- 7.1.2 Cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Non-cleavable Linker
- 7.2.1 Overview
- 7.2.2 Non-cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

8. Antibody Drug Conjugates Market Analysis - by Application

8.1 Blood Cancer
- 8.1.1 Overview
- 8.1.2 Blood Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Brain Cancer
- 8.2.1 Overview
- 8.2.2 Brain Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Breast Cancer
- 8.3.1 Overview
- 8.3.2 Breast Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Ovarian Cancer
- 8.4.1 Overview
- 8.4.2 Ovarian Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Lung Cancer
- 8.5.1 Overview
- 8.5.2 Lung Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

9. Antibody Drug Conjugates Market Analysis - by Target

9.1 HER2
- 9.1.1 Overview
- 9.1.2 HER2: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
9.2 CD22
- 9.2.1 Overview
- 9.2.2 CD22: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
9.3 CD30
- 9.3.1 Overview
- 9.3.2 CD30: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Others
- 9.4.1 Overview
- 9.4.2 Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

10. Antibody Drug Conjugates Market Analysis - by Distribution Channel

10.1 Retail Pharmacies
- 10.1.1 Overview
- 10.1.2 Retail Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Hospital Pharmacies
- 10.2.1 Overview
- 10.2.2 Hospital Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Online Pharmacies
- 10.3.1 Overview
- 10.3.2 Online Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

11. Antibody Drug Conjugates Market - Geographical Analysis

11.1 Overview
11.2 North America
- 11.2.1 North America Antibody Drug Conjugates Market Overview
- 11.2.2 North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.3 North America: Antibody Drug Conjugates Market Breakdown, by Technology
  - 11.2.3.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
- 11.2.4 North America: Antibody Drug Conjugates Market Breakdown, by Application
  - 11.2.4.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
- 11.2.5 North America: Antibody Drug Conjugates Market Breakdown, by Target
  - 11.2.5.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
- 11.2.6 North America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.2.6.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.2.7 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.2.7.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.2.7.2 United States: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.7.2.1 United States: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.2.7.2.2 United States: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.2.7.2.3 United States: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.2.7.2.4 United States: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.2.7.3 Canada: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.7.3.1 Canada: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.2.7.3.2 Canada: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.2.7.3.3 Canada: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.2.7.3.4 Canada: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.2.7.4 Mexico: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.7.4.1 Mexico: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.2.7.4.2 Mexico: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.2.7.4.3 Mexico: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.2.7.4.4 Mexico: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
11.3 Europe
- 11.3.1 Europe Antibody Drug Conjugates Market Overview
- 11.3.2 Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
- 11.3.3 Europe: Antibody Drug Conjugates Market Breakdown, by Technology
  - 11.3.3.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
- 11.3.4 Europe: Antibody Drug Conjugates Market Breakdown, by Application
  - 11.3.4.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
- 11.3.5 Europe: Antibody Drug Conjugates Market Breakdown, by Target
  - 11.3.5.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
- 11.3.6 Europe: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.3.6.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.3.7 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.3.7.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.3.7.2 United Kingdom: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.2.1 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.3.7.2.2 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.3.7.2.3 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.3.7.2.4 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.3.7.3 Germany: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.3.1 Germany: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.3.7.3.2 Germany: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.3.7.3.3 Germany: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.3.7.3.4 Germany: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.3.7.4 France: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.4.1 France: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.3.7.4.2 France: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.3.7.4.3 France: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.3.7.4.4 France: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.3.7.5 Italy: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.5.1 Italy: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.3.7.5.2 Italy: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.3.7.5.3 Italy: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.3.7.5.4 Italy: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.3.7.6 Spain: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.6.1 Spain: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.3.7.6.2 Spain: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.3.7.6.3 Spain: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.3.7.6.4 Spain: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.3.7.7 Rest of Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.7.1 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.3.7.7.2 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.3.7.7.3 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.3.7.7.4 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
11.4 Asia Pacific
- 11.4.1 Asia Pacific Antibody Drug Conjugates Market Overview
- 11.4.2 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
- 11.4.3 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Technology
  - 11.4.3.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
- 11.4.4 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Application
  - 11.4.4.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
- 11.4.5 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Target
  - 11.4.5.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
- 11.4.6 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.4.6.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.4.7 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.4.7.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.4.7.2 China: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.2.1 China: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.4.7.2.2 China: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.4.7.2.3 China: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.4.7.2.4 China: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.4.7.3 Japan: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.3.1 Japan: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.4.7.3.2 Japan: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.4.7.3.3 Japan: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.4.7.3.4 Japan: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.4.7.4 India: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.4.1 India: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.4.7.4.2 India: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.4.7.4.3 India: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.4.7.4.4 India: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.4.7.5 Australia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.5.1 Australia: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.4.7.5.2 Australia: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.4.7.5.3 Australia: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.4.7.5.4 Australia: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.4.7.6 South Korea: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.6.1 South Korea: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.4.7.6.2 South Korea: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.4.7.6.3 South Korea: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.4.7.6.4 South Korea: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.4.7.7 Rest of APAC: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.7.1 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.4.7.7.2 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.4.7.7.3 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.4.7.7.4 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
11.5 Middle East and Africa
- 11.5.1 Middle East and Africa Antibody Drug Conjugates Market Overview
- 11.5.2 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
- 11.5.3 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Technology
  - 11.5.3.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
- 11.5.4 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Application
  - 11.5.4.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
- 11.5.5 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Target
  - 11.5.5.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
- 11.5.6 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.5.6.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.5.7 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.5.7.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.5.7.2 South Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.7.2.1 South Africa: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.5.7.2.2 South Africa: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.5.7.2.3 South Africa: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.5.7.2.4 South Africa: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.5.7.3 Saudi Arabia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.7.3.1 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.5.7.3.2 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.5.7.3.3 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.5.7.3.4 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.5.7.4 United Arab Emirates: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.7.4.1 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.5.7.4.2 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.5.7.4.3 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.5.7.4.4 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.5.7.5 Rest of Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.7.5.1 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.5.7.5.2 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.5.7.5.3 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.5.7.5.4 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
11.6 South and Central America
- 11.6.1 South and Central America Antibody Drug Conjugates Market Overview
- 11.6.2 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
- 11.6.3 South and Central America: Antibody Drug Conjugates Market Breakdown, by Technology
  - 11.6.3.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
- 11.6.4 South and Central America: Antibody Drug Conjugates Market Breakdown, by Application
  - 11.6.4.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
- 11.6.5 South and Central America: Antibody Drug Conjugates Market Breakdown, by Target
  - 11.6.5.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
- 11.6.6 South and Central America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.6.6.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.6.7 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.6.7.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.6.7.2 Brazil: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.6.7.2.1 Brazil: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.6.7.2.2 Brazil: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.6.7.2.3 Brazil: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.6.7.2.4 Brazil: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.6.7.3 Argentina: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.6.7.3.1 Argentina: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.6.7.3.2 Argentina: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.6.7.3.3 Argentina: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.6.7.3.4 Argentina: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.6.7.4 Rest of South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.6.7.4.1 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.6.7.4.2 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.6.7.4.3 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.6.7.4.4 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel

12. Competitive Landscape

12.1.1 Heat Map Analysis
12.1.2 Company Share Analysis:

13. Industry Landscape

13.1 Overview
13.2 Growth Strategies in Antibody Drug Conjugates Market
13.3 Organic Growth Strategies
- 13.3.1 Overview
13.4 Inorganic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 ADC Therapeutics SA
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Pfizer Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 F. Hoffmann-La Roche Ltd
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Daiichi Sankyo Co Ltd
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Financial Overview
- 14.4.4 SWOT Analysis
- 14.4.5 Key Developments
14.5 GSK Plc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Financial Overview
- 14.5.4 SWOT Analysis
- 14.5.5 Key Developments
14.6 Gilead Sciences Inc
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 AstraZeneca Plc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Astellas Pharma Inc
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 RemeGen Co Ltd
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Financial Overview
- 14.9.4 SWOT Analysis
- 14.9.5 Key Developments
14.10 Takeda Pharmaceutical Co Ltd
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
14.11 Merck KGaA
- 14.11.1 Key Facts
- 14.11.2 Business Description
- 14.11.3 Products and Services
- 14.11.4 Financial Overview
- 14.11.5 SWOT Analysis
- 14.11.6 Key Developments
14.12 Johnson & Johnson
- 14.12.1 Key Facts
- 14.12.2 Business Description
- 14.12.3 Products and Services
- 14.12.4 Financial Overview
- 14.12.5 SWOT Analysis
- 14.12.6 Key Developments
14.13 Bristol-Myers Squibb Co
- 14.13.1 Key Facts
- 14.13.2 Business Description
- 14.13.3 Products and Services
- 14.13.4 Financial Overview
- 14.13.5 SWOT Analysis
- 14.13.6 Key Developments
14.14 BioNTech SE
- 14.14.1 Key Facts
- 14.14.2 Business Description
- 14.14.3 Products and Services
- 14.14.4 Financial Overview
- 14.14.5 SWOT Analysis
- 14.14.6 Key Developments
14.15 AbbVie Inc
- 14.15.1 Key Facts
- 14.15.2 Business Description
- 14.15.3 Products and Services
- 14.15.4 Financial Overview
- 14.15.5 SWOT Analysis
- 14.15.6 Key Developments

15. Appendix

15.1 About The Insight Partners